{
  "schemaVersion": 2,
  "eyebrow": "Heart Failure",
  "title": "Acute Heart Failure Diuretic Escalation",
  "summary": "Use an early intravenous loop-diuretic response assessment to distinguish underdosing from true resistance, double inadequate doses promptly, then add sequential nephron blockade selectively while monitoring renal function and electrolytes. Reserve ultrafiltration for failure of a stepped pharmacologic strategy.",
  "seoDescription": "A practical acute heart failure diuretic escalation algorithm using IV loop dosing, urine sodium and output targets, add-on therapy, and ultrafiltration.",
  "clinicalQuestion": "How should intravenous diuretics be titrated and escalated in hospitalized acute heart failure with persistent congestion?",
  "specialty": "Cardiology",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "acute heart failure",
    "diuretic resistance",
    "intravenous furosemide",
    "urine sodium",
    "sequential nephron blockade",
    "acetazolamide",
    "ultrafiltration"
  ],
  "keyTakeaways": [
    "Start IV loop diuretic therapy promptly in clinically congested acute heart failure; use 20–40 mg IV furosemide in loop-naive patients or at least the chronic oral loop-equivalent dose in patients already receiving loop therapy. [8]",
    "At 2 hours, urine sodium below 50–70 mEq/L or urine output below 150 mL/hour indicates an inadequate initial response; double the IV loop dose and reassess rather than waiting for next-day weight change. [22][23]",
    "For persistent congestion despite maximized loop therapy, add a thiazide-type agent first; this improves fluid loss but increases renal dysfunction, hypokalemia, and other electrolyte disturbances. [5][11][19][24]",
    "Acetazolamide 500 mg once daily added to standardized IV loop therapy improves decongestion, but renal-function monitoring remains necessary. [21][24]",
    "Do not use routine ultrafiltration as the next escalation step in cardiorenal acute heart failure: stepped pharmacologic therapy preserved renal function better at 96 hours with similar weight loss and fewer serious adverse events. [19][22]"
  ],
  "sections": [
    {
      "id": "initial-loop-strategy",
      "eyebrow": "First hours",
      "heading": "Start with an adequately dosed intravenous loop diuretic",
      "intro": "Apparent diuretic resistance commonly reflects inadequate initial loop-diuretic exposure rather than failure of the drug class.",
      "paragraphs": [
        "Use IV loop diuretic therapy for acute heart failure with clinically evident congestion requiring decongestion. For patients not taking a loop diuretic, an initial furosemide dose of 20–40 mg IV is guideline-based. For patients on chronic loop therapy, give at least an IV dose equivalent to the oral home dose; position papers support an initial dose of approximately one to two times the oral home dose. [8]",
        "If congestion is substantial or response to the home-equivalent dose is inadequate, a higher IV loop strategy is reasonable. In DOSE, a high-dose strategy of 2.5 times the oral home dose did not improve the 72-hour global symptom assessment versus a home-dose-equivalent strategy, but it produced greater dyspnea relief, weight loss, and net fluid loss. [8][19]",
        "Administer intermittent IV doses initially and judge effectiveness by early natriuresis or urine output, not by symptom trajectory alone. When a dose achieves the response target, continue that dose every 6–12 hours while congestion persists. Continuous furosemide infusion is an option in refractory cases, but it should not substitute for prompt reassessment after an ineffective bolus. [23]"
      ],
      "bullets": [
        "Loop-naive patient: furosemide 20–40 mg IV. [8]",
        "Chronic loop exposure: begin with at least the oral home-dose equivalent administered IV; an initial one- to twofold home-dose approach is used in structured escalation protocols. [8]",
        "When effective, repeat the established IV dose every 6–12 hours until decongestion. [23]"
      ],
      "subsections": [],
      "table": {
        "caption": "Initial IV loop-diuretic dosing and early response assessment in acute heart failure. [8][22][23]",
        "columns": [
          "Clinical setting",
          "Initial action",
          "Response assessment",
          "Next action"
        ],
        "rows": [
          [
            "No chronic loop diuretic",
            "Furosemide 20–40 mg IV. [8]",
            "Check spot urine sodium at 1–2 hours or urine output over the first 2–6 hours. [23]",
            "If urine sodium is below 50–70 mEq/L or urine output is below 150 mL/hour at 2 hours, double the dose. [22][23]"
          ],
          [
            "Chronic loop diuretic use",
            "Give at least the oral home-dose equivalent IV; a one- to twofold home-dose strategy is used in protocolized care. [8]",
            "Use the same early urine sodium or urine-output targets. [22][23]",
            "If targets are met, repeat every 6–12 hours; if not, double and reassess. [23]"
          ],
          [
            "Persistent congestion after an effective loop dose",
            "Continue the effective loop dose every 6–12 hours. [23]",
            "Track clinical decongestion and renal function/electrolytes during continued diuresis. [15][16]",
            "Add a second diuretic only after an adequate loop strategy has failed to achieve decongestion. [11][19]"
          ]
        ]
      }
    },
    {
      "id": "measure-diuretic-response",
      "eyebrow": "Response testing",
      "heading": "Use urine sodium or urine output to identify inadequate natriuresis early",
      "intro": "Early response metrics allow same-day escalation before persistent congestion becomes entrenched.",
      "paragraphs": [
        "Obtain a spot urine sodium concentration 1–2 hours after the initial IV loop dose when catheterized or reliably collected urine is available. A value below 50–70 mmol/L at 2 hours indicates inadequate natriuresis and should trigger dose escalation. A spot sample has shown strong correlation with total sodium excretion and urine output from a 6-hour collection. [21][22][23]",
        "If spot urine sodium is impractical, use hourly urine output. A target above 150 mL/hour at 2 hours supports adequate response; output below this threshold should prompt doubling of the prior IV loop dose, followed by repeat assessment 2 hours later. [23]",
        "European guidance also recognizes a 6-hour urine-output assessment after IV loop administration. Structured urine sodium-guided approaches increase diuretic intensification and natriuresis, but the role of serial urine sodium testing in improving definitive clinical outcomes remains under evaluation. [9][10][22]"
      ],
      "bullets": [
        "Spot urine sodium: obtain 1–2 hours after IV loop administration; below 50–70 mmol/L is inadequate response. [21][22][23]",
        "Urine output alternative: target more than 150 mL/hour; reassess at 2 hours after the initial or escalated dose. [23]",
        "Do not label resistance after one low dose: repeat with a doubled IV loop dose before adding a second nephron-segment agent. [20][23]"
      ],
      "subsections": [
        {
          "heading": "Interpret a creatinine rise in the context of decongestion",
          "paragraphs": [
            "Follow serum creatinine and electrolytes during IV diuretic escalation because loop diuretics and combination therapy can worsen renal function and disturb potassium and sodium balance. A creatinine increase must be interpreted alongside residual congestion and diuretic response rather than used automatically to stop decongestion. [15][16][19]"
          ],
          "bullets": [
            "Escalate laboratory surveillance when adding a thiazide-type diuretic or acetazolamide because combination regimens increase the risk of renal and electrolyte adverse effects. [5][24]",
            "Avoid relying on creatinine- or cystatin C-based estimated GFR as a precise real-time measure of filtration during acute heart failure; both may be misleading in this setting. [17]"
          ]
        }
      ],
      "table": {
        "caption": "Action thresholds for early IV loop-diuretic response. [21][22][23]",
        "columns": [
          "Metric",
          "Timing after IV loop dose",
          "Adequate response",
          "Inadequate response and action"
        ],
        "rows": [
          [
            "Spot urine sodium",
            "1–2 hours. [21][23]",
            "More than 50–70 mEq/L. [23]",
            "Below 50–70 mEq/L: double the loop-diuretic dose and repeat assessment. [22][23]"
          ],
          [
            "Urine output",
            "Assess at 2 hours; hourly monitoring may continue through 6 hours. [10][23]",
            "More than 150 mL/hour. [23]",
            "Below 150 mL/hour: double the loop-diuretic dose and reassess after the repeat dose. [23]"
          ],
          [
            "Persistent congestion despite response targets",
            "During serial daily assessment.",
            "Ongoing urine output does not alone establish complete decongestion.",
            "Continue effective loop dosing and assess for residual congestion before discharge because incomplete decongestion is associated with rehospitalization and mortality. [5][22]"
          ]
        ]
      }
    },
    {
      "id": "escalate-loop-dose",
      "eyebrow": "Loop optimization",
      "heading": "Double an ineffective loop dose before declaring diuretic resistance",
      "intro": "Dose escalation should be response-guided and repeated promptly until natriuresis or urine-output targets are reached.",
      "paragraphs": [
        "When the initial IV loop dose fails to achieve urine sodium above 50–70 mEq/L or urine output above 150 mL/hour at 2 hours, double the prior dose and repeat the same response measurement 2 hours later. Continue this loop-dose escalation until the response target is achieved or the maximum protocol dose is reached. [23]",
        "Once a response is established, maintain the effective dose every 6–12 hours rather than reverting to the ineffective starting dose. In a practical stepped strategy, persistent congestion with urine output below 3–4 L over 24 hours despite high-dose or maximized loop therapy is a trigger to add another diuretic mechanism. [19]",
        "Use the lowest loop dose that produces meaningful decongestion once euvolemia is approaching, because loop treatment requires an ongoing balance between decongestion and renal dysfunction, electrolyte disturbance, and neurohormonal activation. [3][8][19]"
      ],
      "bullets": [
        "Failure at 2 hours: double the preceding IV loop dose. [23]",
        "Success at 2 hours: continue the effective dose every 6–12 hours. [23]",
        "Failure despite maximized loop therapy and urine output below 3–4 L/day with persistent congestion: proceed to adjunctive therapy. [19]"
      ],
      "subsections": [],
      "table": {
        "caption": "Stepwise escalation after an inadequate IV loop response. [19][23]",
        "columns": [
          "Step",
          "Trigger",
          "Action",
          "Reassessment"
        ],
        "rows": [
          [
            "1. Initial loop dose",
            "Clinical congestion requiring IV decongestion.",
            "Use loop-naive or chronic-loop starting strategy. [8]",
            "Spot urine sodium at 1–2 hours or urine output by 2 hours. [23]"
          ],
          [
            "2. Loop-dose escalation",
            "Urine sodium below 50–70 mEq/L or urine output below 150 mL/hour. [22][23]",
            "Double the prior IV loop dose. [23]",
            "Repeat urine sodium or output assessment 2 hours later. [23]"
          ],
          [
            "3. Sequential blockade",
            "Persistent congestion and inadequate output despite high-dose/maximized loop therapy; practical threshold below 3–4 L urine output in 24 hours. [19]",
            "Add a thiazide-type diuretic first; consider acetazolamide as an alternative add-on. [19][21]",
            "Monitor creatinine and electrolytes closely. [5][15][24]"
          ],
          [
            "4. Rescue therapy",
            "Failure of stepped pharmacologic decongestion.",
            "Consider ultrafiltration selectively rather than routinely. [19]",
            "Compare renal trajectory, weight loss, adverse events, and ongoing congestion. [22]"
          ]
        ]
      }
    },
    {
      "id": "combination-diuretics",
      "eyebrow": "Sequential blockade",
      "heading": "Add a second diuretic only after loop optimization fails",
      "intro": "Sequential nephron blockade improves short-term fluid removal but shifts risk toward electrolyte depletion and renal dysfunction.",
      "paragraphs": [
        "For resistant edema that does not respond to higher loop-diuretic doses, add a thiazide-type diuretic to block distal tubular sodium reabsorption. European guidance gives loop-thiazide combination therapy a class IIa, level B recommendation in this situation. In CLOROTIC, oral hydrochlorothiazide added to IV furosemide improved diuretic response and produced greater 72-hour weight loss than placebo. [11][21]",
        "Use thiazide augmentation with active electrolyte and renal surveillance. Across CLOROTIC analyses, combination treatment increased fluid loss but was associated with more renal-function and electrolyte disturbances; meta-analytic evidence also associates loop-thiazide therapy with worsening renal function and hypokalemia. [5][24]",
        "Do not exclude thiazide augmentation solely because eGFR is below 30 mL/min/1.73 m². The historical assumption of absent efficacy at this threshold has been challenged, and CLOROTIC found no significant interaction between eGFR subgroup and hydrochlorothiazide effects on diuretic response or safety endpoints. [11]"
      ],
      "bullets": [
        "Preferred first add-on after an optimized loop strategy fails: thiazide-type diuretic. [19][23]",
        "Hydrochlorothiazide plus IV furosemide improves diuretic response, including in patients with impaired kidney function, but requires monitoring for hypokalemia, hyponatremia, and renal dysfunction. [11][24]",
        "Evidence does not establish a preferred thiazide-like agent between oral metolazone and IV chlorothiazide in acute heart failure with renal dysfunction. [12]"
      ],
      "subsections": [
        {
          "heading": "Use acetazolamide as an alternative proximal-tubule add-on",
          "paragraphs": [
            "Acetazolamide 500 mg once daily added to standardized IV loop diuretics improved decongestion in acute decompensated heart failure with volume overload. It is a reasonable add-on when persistent congestion remains after loop optimization, particularly when a proximal-tubule strategy is preferred over thiazide escalation. [2][21]",
            "Monitor renal function and electrolytes after acetazolamide initiation. Network meta-analysis data associate loop plus acetazolamide with worsening renal function, although thiazide combinations carry a clearer hypokalemia signal. [24]"
          ],
          "bullets": [
            "Dose supported by ADVOR-related evidence: acetazolamide 500 mg once daily as an add-on to standardized IV loop therapy. [21]",
            "Expected tradeoff: improved decongestion with potential worsening renal function requiring laboratory monitoring. [21][24]"
          ]
        },
        {
          "heading": "Do not use SGLT2 inhibitors as an acute substitute for loop escalation",
          "paragraphs": [
            "SGLT2 inhibitors may have favorable renal safety signals and may reduce heart-failure hospitalization in selected diuretic-resistance studies, but the comparative evidence is indirect and imprecise. In acute congestion, use response-guided IV loop optimization first; consider SGLT2 inhibitor therapy in hemodynamically stable patients as part of broader heart-failure treatment rather than as a replacement for immediate natriuretic escalation. [6][19]"
          ],
          "bullets": [
            "SGLT2 inhibitor evidence in diuretic resistance remains exploratory relative to established loop escalation and sequential nephron blockade. [6]",
            "Do not delay loop-dose escalation while awaiting the slower clinical effects of a disease-modifying therapy. [19][23]"
          ]
        }
      ],
      "table": {
        "caption": "Adjunctive strategies for persistent congestion after optimized IV loop therapy. [5][6][11][19][21][24]",
        "columns": [
          "Strategy",
          "When to use",
          "Expected benefit",
          "Major tradeoff"
        ],
        "rows": [
          [
            "Thiazide-type diuretic plus loop",
            "Resistant edema after failure to respond to increased loop dose. [11]",
            "Greater diuretic response and fluid loss; hydrochlorothiazide improved 72-hour weight loss in CLOROTIC. [11][21]",
            "Higher risk of renal-function and electrolyte disturbances, including hypokalemia. [5][24]"
          ],
          [
            "Acetazolamide 500 mg once daily plus loop",
            "Persistent volume overload after loop optimization when an alternative add-on strategy is selected. [21]",
            "Improved decongestion with standardized IV loop therapy. [21]",
            "Worsening renal function signal; monitor kidney function and electrolytes. [24]"
          ],
          [
            "SGLT2 inhibitor plus loop",
            "Selected stable patients; not as immediate rescue for an inadequate initial loop response. [6]",
            "Potential reduction in rehospitalization with favorable renal signal in selected trials. [6]",
            "Indirect comparisons and wide confidence intervals limit certainty for acute resistance treatment. [6]"
          ]
        ]
      }
    },
    {
      "id": "ultrafiltration-and-discharge",
      "eyebrow": "Rescue and transition",
      "heading": "Reserve ultrafiltration for pharmacologic failure and discharge only after decongestion",
      "intro": "Mechanical fluid removal is a rescue option, not a routine substitute for a structured diuretic escalation strategy.",
      "paragraphs": [
        "Consider ultrafiltration only when adequate loop dosing and adjunctive pharmacologic strategies fail to achieve decongestion. In CARRESS-HF, a stepped pharmacologic algorithm was superior to ultrafiltration for preservation of renal function at 96 hours, with similar weight loss. [19][20]",
        "In the CARRESS-HF comparison, serum creatinine increased by 0.23 mg/dL with ultrafiltration versus decreased by 0.04 mg/dL with stepped pharmacologic therapy at 96 hours; weight loss was similar, and serious adverse events through 60 days were more frequent with ultrafiltration (72% versus 57%). These findings favor continued pharmacologic escalation in patients who remain candidates for it. [22]",
        "Before discharge, confirm that congestion has been meaningfully resolved rather than accepting symptomatic improvement alone. Residual congestion at discharge is associated with higher heart-failure readmission and mortality, making completion of decongestion a central inpatient target. [5][22]"
      ],
      "bullets": [
        "Ultrafiltration indication: persistent congestion after failure of stepped pharmacologic decongestion. [19]",
        "In cardiorenal acute heart failure, favor stepped pharmacologic treatment over routine ultrafiltration to preserve renal function at 96 hours. [19][22]",
        "Discharge priority: avoid residual congestion, which is associated with subsequent rehospitalization and death. [5][22]"
      ],
      "subsections": [],
      "table": {
        "caption": "Ultrafiltration versus stepped pharmacologic therapy in CARRESS-HF. [22]",
        "columns": [
          "Outcome",
          "Ultrafiltration",
          "Stepped pharmacologic therapy",
          "Clinical implication"
        ],
        "rows": [
          [
            "Change in serum creatinine at 96 hours",
            "+0.23 ± 0.70 mg/dL. [22]",
            "−0.04 ± 0.53 mg/dL. [22]",
            "Stepped pharmacologic therapy better preserved renal function. [22]"
          ],
          [
            "Weight loss at 96 hours",
            "5.7 ± 3.9 kg. [22]",
            "5.5 ± 5.1 kg. [22]",
            "No meaningful weight-loss advantage for ultrafiltration. [22]"
          ],
          [
            "Serious adverse events through 60 days",
            "72%. [22]",
            "57%. [22]",
            "Use ultrafiltration selectively after pharmacologic failure. [22]"
          ]
        ]
      }
    }
  ],
  "faq": [],
  "references": [
    {
      "number": 1,
      "title": "Vascular (dys)function in the failing heart | Nature Reviews Cardiology",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41569-025-01163-w",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 2,
      "title": "Efficacy of combining acetazolamide with loop diuretics versus double dose loop diuretics for decongestion in patients with chronic kidney disease: a randomized controlled trial | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-026-50753-2",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 3,
      "title": "Loop Diuretic Applications in Heart Failure Management | Cardiology | Cardiovascular Medicine and Haematology | Health sciences | Topics | Nature Index",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/nature-index/topics/l4/loop-diuretic-applications-in-heart-failure-management",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 4,
      "title": "Guideline-directed medical strategies for the co-management of ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s43856-025-00951-2",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 5,
      "title": "Simplifying Treatment of Congestion: Diuretic Response With Sequential Nephron Blockade Is Independent of Ejection Fraction",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jchf.2024.05.024",
      "authors": "www.jacc.org",
      "host": "www.jacc.org"
    },
    {
      "number": 6,
      "title": "Comparative Strategies to Overcome Diuretic Resistance in Heart Failure: A Network Meta-Analysis",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2026.102617",
      "authors": "www.jacc.org",
      "host": "www.jacc.org"
    },
    {
      "number": 7,
      "title": "Simplifying Treatment of Congestion: Diuretic Response With Sequential Nephron Blockade Is Independent of Ejection Fraction | JACC: Heart Failure",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/abs/10.1016/j.jchf.2024.05.024",
      "authors": "www.jacc.org",
      "host": "www.jacc.org"
    },
    {
      "number": 8,
      "title": "Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study - Dauw - 2021 - ESC Heart Failure - Wiley Online Library",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/ehf2.13666",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 9,
      "title": "Rationale and Design of the DECONGEST (Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment) Study - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1071916424003609",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 10,
      "title": "Diuretic resistance measured by sodium excretion and urine output in acute heart failure: The DIURESIS-AHF study - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0914508725001716",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 11,
      "title": "Combining loop and thiazide diuretics for acute heart failure across the estimated glomerular filtration rate spectrum: A post‐hoc analysis of the CLOROTIC trial - Trullàs - 2023 - European Journal of Heart Failure - Wiley Online Library",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.2988",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 12,
      "title": "Metolazone Versus Chlorothiazide as Add-On Therapy to Loop Diuretics in Patients with Acute Decompensated Heart Failure and Renal Insufficiency - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1071916413004570",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 13,
      "title": "Practical Outpatient Management of Worsening Chronic Heart Failure",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/eurjhf/article/24/5/750/8364290",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 14,
      "title": "Diuretic - an overview | ScienceDirect Topics",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/diuretic",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 15,
      "title": "Advanced chronic kidney disease coexisting with heart failure",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/ckj/article/18/5/sfaf128/8124383",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 16,
      "title": "Renal function, electrolytes, and congestion monitoring in heart failure",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/eurheartjsupp/article/21/Supplement_M/M25/5691317",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 17,
      "title": "KDIGO 2024 Clinical Practice Guideline for the Evaluation and ...",
      "detail": "www.kidney-international.org",
      "url": "https://www.kidney-international.org/article/%20S0085-2538%2823%2900766-4/fulltext",
      "authors": "www.kidney-international.org",
      "host": "www.kidney-international.org"
    },
    {
      "number": 18,
      "title": "Diuretics in critically ill patients: a narrative review of their ...",
      "detail": "www.bjanaesthesia.org",
      "url": "https://www.bjanaesthesia.org/article/S0007-0912(25)00159-X/fulltext",
      "authors": "www.bjanaesthesia.org",
      "host": "www.bjanaesthesia.org"
    },
    {
      "number": 19,
      "title": "Diuretic Treatment in Heart Failure: A Practical Guide for Clinicians",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11313642",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 20,
      "title": "Systematic Review on the Management of Diuretic Resistance in Acute Heart Failure across the Spectrum of Kidney Disease",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12215157",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 21,
      "title": "Kidney Disease and Heart Failure: Recent Advances and Current Challenges",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13092174",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 22,
      "title": "From Hospital to Home",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11342447",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 23,
      "title": "[PDF] How do we maximize diuresis in acute decompensated heart failure?",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/content/ccjom/89/10/561.full-text.pdf",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org"
    },
    {
      "number": 24,
      "title": "ESC 365 - Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials",
      "detail": "esc365.escardio.org",
      "url": "https://esc365.escardio.org/journal/90306",
      "authors": "esc365.escardio.org",
      "host": "esc365.escardio.org"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "Vascular (dys)function in the failing heart | Nature Reviews Cardiology",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41569-025-01163-w",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Diuretic strategies for loop diuretic resistance in acute heart failure: decompensated heart failure: 2022 AHA/ACC/HFSA guideline for the",
      "score": 0.6937432
    },
    {
      "number": 2,
      "title": "Efficacy of combining acetazolamide with loop diuretics versus double dose loop diuretics for decongestion in patients with chronic kidney disease: a randomized controlled trial | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-026-50753-2",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Article \nCAS \nPubMed \nPubMed Central \nGoogle Scholar\n\nGuo, L. et al. Diuretic resistance in patients with kidney disease: Challenges and opportunities. Biomed. Pharmacother. 157, 114058.  (2023).\n\nArticle \nCAS \nPubMed \nGoogle Scholar\n\nSiddiqi, A. K. et al. Acetazolamide as an Adjunctive Diuretic The",
      "score": 0.68344116
    },
    {
      "number": 3,
      "title": "Loop Diuretic Applications in Heart Failure Management | Cardiology | Cardiovascular Medicine and Haematology | Health sciences | Topics | Nature Index",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/nature-index/topics/l4/loop-diuretic-applications-in-heart-failure-management",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Loop diuretics are cornerstone therapies for the relief of congestion in patients with heart failure. By inhibiting the Na⁺‐K⁺‐2Cl⁻ cotransporter in the thick ascending limb of the loop of Henle, these agents promote natriuresis and diuresis, thereby reducing intravascular volume, lowering cardiac p",
      "score": 0.6747586
    },
    {
      "number": 4,
      "title": "Guideline-directed medical strategies for the co-management of ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s43856-025-00951-2",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "In 2022, the American Heart Association issued a scientific statement identifying MASLD as a risk factor for ASCVD. They offered proposed pathophysiology, diagnostic and screening strategies, and potential interventions21.\"). Other than this statement regarding MASLD and ASCVD, no formal guidance ha",
      "score": 0.5174983
    },
    {
      "number": 5,
      "title": "Simplifying Treatment of Congestion: Diuretic Response With Sequential Nephron Blockade Is Independent of Ejection Fraction",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jchf.2024.05.024",
      "authors": "www.jacc.org",
      "host": "www.jacc.org",
      "snippet": "Treatment with HCTZ was associated with a higher incidence of renal function and electrolyte disturbance. Whether this translated into a higher risk of long-term adverse events is unknown. This is perhaps more important in HFrEF, where worsening renal function often results in less optimization of d",
      "score": 0.7120925
    },
    {
      "number": 6,
      "title": "Comparative Strategies to Overcome Diuretic Resistance in Heart Failure: A Network Meta-Analysis",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2026.102617",
      "authors": "www.jacc.org",
      "host": "www.jacc.org",
      "snippet": "### Conclusions\n\nIn HF with diuretic resistance, sodium-glucose cotransporter 2 inhibitors may lower rehospitalization with a favorable renal profile, whereas nephron-segment add-ons enhance short-term decongestion but warrant AKI/electrolyte monitoring; rankings are exploratory, and choices should ",
      "score": 0.6426349
    },
    {
      "number": 7,
      "title": "Simplifying Treatment of Congestion: Diuretic Response With Sequential Nephron Blockade Is Independent of Ejection Fraction | JACC: Heart Failure",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/abs/10.1016/j.jchf.2024.05.024",
      "authors": "www.jacc.org",
      "host": "www.jacc.org",
      "snippet": "Title: Simplifying Treatment of Congestion: Diuretic Response With Sequential Nephron Blockade Is Independent of Ejection Fraction | JACC: Heart Failure\nYou can view the full content in the following formats:. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial",
      "score": 0.53531766
    },
    {
      "number": 8,
      "title": "Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study - Dauw - 2021 - ESC Heart Failure - Wiley Online Library",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/ehf2.13666",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "The Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure (ENACT-HF) study is an international, multicentre, non-randomized, open-label, pragmatic study in AHF patients on chronic loop diuretic therapy, admitted to the hospital for intravenous loop diuretic therapy, aiming to enrol 500",
      "score": 0.77650476
    },
    {
      "number": 9,
      "title": "Rationale and Design of the DECONGEST (Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment) Study - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1071916424003609",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Title: Rationale and Design of the DECONGEST (Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment) Study - ScienceDirect\n# Rationale and Design of the DECONGEST (Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial S",
      "score": 0.6628188
    },
    {
      "number": 10,
      "title": "Diuretic resistance measured by sodium excretion and urine output in acute heart failure: The DIURESIS-AHF study - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0914508725001716",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Title: Diuretic resistance measured by sodium excretion and urine output in acute heart failure: The DIURESIS-AHF study - ScienceDirect\n# Original Article Diuretic resistance measured by sodium excretion and urine output in acute heart failure: The DIURESIS-AHF study. We assessed the association bet",
      "score": 0.6260562
    },
    {
      "number": 11,
      "title": "Combining loop and thiazide diuretics for acute heart failure across the estimated glomerular filtration rate spectrum: A post‐hoc analysis of the CLOROTIC trial - Trullàs - 2023 - European Journal of Heart Failure - Wiley Online Library",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/ejhf.2988",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "There were no significant differences observed with the addition of HCTZ in terms of diuretic response, mortality or rehospitalizations, or safety endpoints (impaired renal function, hyponatraemia, and hypokalaemia) among the three eGFR groups (all *p*-values for interaction were no significant). Th",
      "score": 0.60274047
    },
    {
      "number": 12,
      "title": "Metolazone Versus Chlorothiazide as Add-On Therapy to Loop Diuretics in Patients with Acute Decompensated Heart Failure and Renal Insufficiency - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1071916413004570",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Title: Metolazone Versus Chlorothiazide as Add-On Therapy to Loop Diuretics in Patients with Acute Decompensated Heart Failure and Renal Insufficiency - ScienceDirect\n## Article preview. ## Journal of Cardiac Failure. Volume 19, Issue 8, Supplement, August 2013, Page S84. # Clinical Care/Management ",
      "score": 0.63723457
    },
    {
      "number": 13,
      "title": "Practical Outpatient Management of Worsening Chronic Heart Failure",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/eurjhf/article/24/5/750/8364290",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "Thiazide-like diuretics can be used in severe HF patients who responded poorly to loop diuretics in a sequential nephron blockade strategy. These diuretic",
      "score": 0.60861784
    },
    {
      "number": 14,
      "title": "Diuretic - an overview | ScienceDirect Topics",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/diuretic",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "•\nHCT is available in a variety of tablet sizes, some of which represent combination products. HCT is often formulated with spironolactone (25 mg of each in the 50-mg tablet) or triamterene (to spare potassium) as these combinations increase the diuretic effect while sparing potassium.\n\n•\nThe usual ",
      "score": 0.5996498
    },
    {
      "number": 15,
      "title": "Advanced chronic kidney disease coexisting with heart failure",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/ckj/article/18/5/sfaf128/8124383",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "Diuretics can lead to electrolyte imbalances and can worsen renal function, requiring frequent monitoring and dose adjustments. This is",
      "score": 0.5634506
    },
    {
      "number": 16,
      "title": "Renal function, electrolytes, and congestion monitoring in heart failure",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/eurheartjsupp/article/21/Supplement_M/M25/5691317",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "Eur Heart J Cardiovasc Pharmacother Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives Eur Heart J Cardiovasc Pharmacother Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with ",
      "score": 0.5189612
    },
    {
      "number": 17,
      "title": "KDIGO 2024 Clinical Practice Guideline for the Evaluation and ...",
      "detail": "www.kidney-international.org",
      "url": "https://www.kidney-international.org/article/%20S0085-2538%2823%2900766-4/fulltext",
      "authors": "www.kidney-international.org",
      "host": "www.kidney-international.org",
      "snippet": "Crossref\n\nGoogle Scholar\n\n136.\n\nCosta, E. ∙ Silva, V.T. ∙ Gil, Jr., L.A. ...\n\nA prospective cross-sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors\n\n_Kidney Int._ 2022; 101:607-614\n\nFull Text\n\nFull Text (PDF)\n\nScopus (0)\n\nPubMed\n\nGoogle S",
      "score": 0.44116792
    },
    {
      "number": 18,
      "title": "Diuretics in critically ill patients: a narrative review of their ...",
      "detail": "www.bjanaesthesia.org",
      "url": "https://www.bjanaesthesia.org/article/S0007-0912(25)00159-X/fulltext",
      "authors": "www.bjanaesthesia.org",
      "host": "www.bjanaesthesia.org",
      "snippet": "Diuretics remain the cornerstone therapy of critically ill patients with volume overload as a result of cardiac failure, acute kidney injury or aggressive",
      "score": 0.25510508
    },
    {
      "number": 19,
      "title": "Diuretic Treatment in Heart Failure: A Practical Guide for Clinicians",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11313642",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "##  vs. high-dose (2.5× home dose) loop diuretics among patients with acute decompensated heart failure and found that, although there was no difference in the primary outcome (global assessment of symptoms and change in creatinine) at 72 h, it did show that high-dose loop diuretics was associated w",
      "score": 0.81630427
    },
    {
      "number": 20,
      "title": "Systematic Review on the Management of Diuretic Resistance in Acute Heart Failure across the Spectrum of Kidney Disease",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12215157",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "| Ultrafiltration: 2.2±0.8 |\n| Loop diuretics: 1.9±0.6 |\n| Bart et al.  (CARESS trial) | 2012 | Ultrafiltration (_N_ = 94) | Stepped pharmacological therapy (_N_ = 94) | AHF population with baseline eGFR <60 mL/min/1.73 m 2 | SCr values (mg/dL) | Ultrafiltration vs. stepped pharmacological therapy: ",
      "score": 0.8029425
    },
    {
      "number": 21,
      "title": "Kidney Disease and Heart Failure: Recent Advances and Current Challenges",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13092174",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "For hospitalized patients, diuretic strategies include sequential nephron blockade, combination therapy, and tailored delivery. In the CARRESS Study (Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome), the addition of metolazone was a",
      "score": 0.77751994
    },
    {
      "number": 22,
      "title": "From Hospital to Home",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11342447",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "−0.30±0.42 (−0.60 to 0.00) (ultrafiltration) vs−0.26±0.30 (−0.70 to 0.10) (loop diuretics), _P_=0.829 CARRESS-HF26\n\n188 (28%)\n\nAquadex System 100 at a fixed rate of 200 ml/hour until decongestion achieved vs stepped pharmacologic therapy with diuretic agents dosed to maintain urine output 3-5 l/dayC",
      "score": 0.7730283
    },
    {
      "number": 23,
      "title": "[PDF] How do we maximize diuresis in acute decompensated heart failure?",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/content/ccjom/89/10/561.full-text.pdf",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org",
      "snippet": "(instead of > 0.3 mg/dL) has been suggested as true renal dysfunction requiring further workup.2 Recent data suggest that using urine output and spot urine sodium to predict short-term responsive­ ness to intravenous loop diuretics in ADHF permits more timely adjustments to therapy (Figure 2).1–3 Wi",
      "score": 0.7644879
    },
    {
      "number": 24,
      "title": "ESC 365 - Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials",
      "detail": "esc365.escardio.org",
      "url": "https://esc365.escardio.org/journal/90306",
      "authors": "esc365.escardio.org",
      "host": "esc365.escardio.org",
      "snippet": "Title: ESC 365 - Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials\n# Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials. Several diuretic strategies, including f",
      "score": 0.7185356
    }
  ],
  "publishedAt": "2026-09-15T21:56:09.359598+00:00",
  "updatedAt": "2026-09-15T21:56:09.359598+00:00",
  "readingMinutes": 7,
  "slug": "acute-heart-failure-diuretic-escalation"
}